PharmAla Biotech Marks a Milestone with LaNeo Capsules
In an exciting development for the biotechnology sector, PharmAla Biotech Holdings Inc. has successfully completed the release testing of its first batch of Australian-made LaNeo™ MDMA 40mg capsules. This achievement represents a significant step forward in the company’s commitment to advancing the use of MDXX class molecules, specifically MDMA.
Successful Collaboration and Progress
PharmAla, known for its innovative approach to research and development, proudly announced its completion of this first batch in partnership with Cortexa. Farnoud Kazemzadeh, the COO of PharmAla Biotech, expressed excitement about this milestone. He mentioned that this initial batch will not only bolster ongoing operations in Australia but also support broader global initiatives. Furthermore, he hinted at a busy production schedule for the upcoming year, which includes plans to develop and release 20mg capsules, along with the encapsulation of the first batch of ALA-002 capsules.
Delivery to Orygen Institute
In conjunction with the testing milestone, PharmAla also successfully delivered its first batch of Australian-made capsules to the Orygen Institute. This shipment, pivotal for supporting a Phase 3 trial focused on addressing social anxiety in autistic youth, marks the second delivery to Orygen under PharmAla’s commitment to providing high-quality MDMA products for clinical research.
Conclusion of Contract with Orygen
This latest shipment signifies the conclusion of PharmAla’s contractual obligations with Orygen, highlighting the successful cooperation between the two organizations in advancing clinical studies.
Understanding PharmAla's Vision
Established with the fundamental goal of addressing the global backlog of clinical-grade MDMA, PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC:MDXXF) has positioned itself as a leader in the field. The company not only aims to facilitate clinical trials but also aspires to bring novel drugs to market within the MDXX class. With a keen focus on regulatory compliance and strong relationships with governing bodies, PharmAla remains committed to its mission of pioneering patient treatments and innovative drug development.
Company Contact Information
If you would like to learn more about PharmAla's initiatives, please reach out to:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is PharmAla Biotech focusing on?
PharmAla Biotech is dedicated to the research, development, and manufacturing of MDXX class molecules, primarily MDMA.
What recent achievement has PharmAla completed?
The company successfully completed the release testing of its first batch of LaNeo™ MDMA 40mg capsules made in Australia.
What is LaNeo?
LaNeo is PharmAla's MDMA product intended for clinical and therapeutic use.
Who is the COO of PharmAla Biotech?
Farnoud Kazemzadeh serves as the Chief Operating Officer of PharmAla Biotech.
What role does PharmAla play in the psychedelic industry?
PharmAla is a leader in provisioning clinical-grade MDMA for patient treatments, contributing significantly to clinical trials and innovative drug development.